Rat tissues were surveyed for proteins which bind cGMP. Binding activity was high in extracts of lung, cerebellum, and small intestine, but was low in those of liver, adipose tissue, and skeletal muscle. DEAE-cellulose chromatography resolved two peaks of cGMP-binding activity in most tissues. The binding protein in peak 1 was eluted in the flowthrough volume and was most abundant in extracts of intestine.
Guanosine 3':5'-cyclic monophosphate (cGMP) is found in mammalian cells at concentrations of less than 0.1 ,uM with the possible exceptions of lung and cerebellum (1) . Although intracellular cGMP may rise and fall dramatically under certain conditions (2) (3) (4) , no physiological function for the nucleotide has been established. The proposal by Kuo and others (5) (6) (7) (8) that cGMP activates a protein kinase in mammalian systems has considerable support. However, the kinase is reported to be relatively unstable and has resisted extensive purification. It has also been proposed by Green and Martin (9, 10) that cGMP stimulates phosphoribosyl pyrophosphate synthetase from cultured HTC cells, suggesting a role for the nucleotide in the regulation of DNA synthesis. Verification is needed, however, to establish this proposal and to show that it applies to other cells.
It would seem probable that the cellular processes regulated by cGMP originate with binding of the nucleotide to specific receptor substances, presumably proteins. Our approach, therefore, to the question of function has been to look for cGMP-binding proteins in cells. Several reports of such proteins in mammalian tissues have already appeared. Sold and Hofmann reported the presence of cGMP-binding activity in rat cerebellum (11) . More recently, a cGMP-binding protein was observed in the adrenal cortex by Gill and Kanstein (12) . Takai et al. (8) and Nakazawa and Sano (13) showed cGMP-binding activity associated with cGMP-dependent protein kinase activity, but specific binding activity was not demonstrated. In some studies, interference by other nucleotides was observed when the binding was measured at pH 4 Preparation of the cGMP-Binding Proteins. Male Sprague-Dawley rats (200-300 g) were decapitated and the tissues were quickly excised, rinsed in 20 mM sodium phosphate-2 mM EDTA, pH 7.0, and homogenized in 5 volumes (wt/vol) of the same buffer at 40. The homogenate was centrifuged at 12,000 X g for 20 min. For purification of the lung binding proteins approximately 35 ml of the supernatant were applied to a DEAE-cellulose column (1.6 X 8 cm) equilibrated with the same buffer. The column was rinsed with 10 volumes of buffer and eluted with a linear gradient of NaCl from 0 to 0.4 M. Fractions (about 8 ml) were collected and those with cGMP-binding activity were pooled and dialyzed against 20 mM sodium phosphate-2 mM EDTA, pH 7.0. In some cases, the peak 2 binding protein was concentrated by precipitation with 50% saturated ammonium sulfate followed by extensive dialysis against the same buffer. Other purification methods are described in the figure legends.
Cyclic Nucleotide Binding Assays. The binding assay was performed in a total volume of 0.1 ml of sodium phosphate buffer at pH 7.0 containing 0.5 MM 3H-labeled (0.1 ,uCi) cyclic nucleotide (either cGMP or cAMP) and, in some cases, 10,uM of the other nonradioactive nucleotide (either cAMP or cGMP). The binding was initiated by the addition of 90 ,ul of protein and tubes were incubated at 4°for 30 min. Free and bound 3H-labeled cyclic nucleotides were separated by the Gilman technique (15) on Millipore filters which were dried at 150°and counted in a toluene-based scintillant. In order to assess the retention of the nucleotide protein complex on the filters, parallel assays were performed in which bound [3H]cGMP was separated on a Sephadex G-25 column (0.9 X 10 cm) and counted. Estimates of bound cGMP by both methods agreed closely. Protein was determined by the method of Lowry et al. (16) .
Cyclic GMP-Dependent Protein Kinase Assay. Cyclic GMP-dependent protein kinase was assayed using a system (about 300 cpm/pmol) and 30 MAg of type II-A histone were contained in a volume of 0.1 ml unless otherwise specified. The concentration of cGMP when present was 0.5 ,M. Assays were incubated at 300 for 15 min, and were terminated by the method of Corbin and Reimann (17) . One unit of enzyme activity is defined as the amount of enzyme necessary to catalyze the transfer of 1 pmol Of 3UP to histone in 1 min.
Molecular Weight Determinations. One milliliter of the peak 2 binding fraction which had been precipitated by 50% saturated ammonium sulfate and dialyzed was chromatographed on a Sepharose 6B column (1.5 X 87 cm) equilibrated with 50 mM Tris-HCl-l mM EDTA, pH 7.5. The column was calibrated with several marker proteins. From the elution data, the Stokes radius was determined. The sedimentation coefficient was obtained from sucrose density gradient centrifugation according to the method of Martin and Ames (18) . The molecular weights and frictional coefficients were calculated from the Stokes radii and sedimentation coefficients according to the method of Siegel and Monty (19) .
RESULTS
The profiles of cGMP-and cAMP-binding activities in extracts of rat lung eluted from a DEAE-cellulose column are shown in Fig. IA The histone kinase activity in peak 1 is not affected by cGMP or cAMP (Fig. 1A) . Cyclic GMP-dependent protein kinase activity is found only in peak 2. The large peak of activity eluted by 0.2 M NaCl is stimulated 5-fold by cAMP but virtually not at all by cGMP (not shown). It coincides with the cAMP-binding activity and.is probably a Type II isozyme of cAMP-dependent protein kinase (20) . The cGMP-dependent protein kinase activity of peak 2 could be detected only in the presence of low concentrations of histone (10-50 Mug/100 Mul). At higher concentrations, little stimulation of kinase activity by cGMP is observed (not shown).
The binding of [3H]cGMP to peak 2 as a function of time and pH is shown in Fig. 2A (Fig. 3) . A similar constant is observed for peak 1. In the absence of 2-mercaptoethanol, the Scatchard plots for peak 1 Fig. 4 that lung, cerebellum, and intestine contain the greatest amount of binding activity. It is also apparent (Fig. 4) that the relative amounts of binding in peak 1 and 2 vary from tissue to tissue.
The binding activity in intestine is almost all in peak 1, whereas in cerebellum it is mostly in peak 2. It is interesting to note that the binding activity in peak 2 from heart seems to elute at a higher salt concentration, suggesting some heterogeneity of the binding activity.
Peak 2 from lung elutes as one main peak from a Sepharose 6B column (data not shown), and sediments as a single peak at about 8 S on sucrose density gradients, as shown in Fig. 5 . On the other hand, the binding activity from the small intestine (peak 1) has a sedimentation coefficient of 6 that the values were not determined. Peak 1 and peak 2 were obtained by DEAE-cellulose chromatography as described in Materials and Methods. the smaller protein (peak 1) is a subunit or breakdown product of the other, although no evidence has been gathered to support this contention. By analogy, it can be pointed out that heterogeneity of cAMP-dependent protein kinases exists in mammalian tissues (20) . Several criteria can be suggested to evaluate whether a protein which binds cGMP is a physiological receptor. These are (i) the KD should be low enough (<0.1 uM) that appreciable binding can occur at the concentrations of nucleotide and at the pH found within the cells; (ii) the binding should be specific enough that it will take place despite the presence of other related compounds, usually at very much higher concentrations; (iii) the quantity of binding proteins might be expected to be greater in cell types in which the levels of cGMP are high (i.e., lung and cerebellum); and (iv) the binding protein should be distinct from enzymes involved in the formation or degradation of the nucleotide. Once the above characteristics have been demonstrated, a search for function can be undertaken along the lines established in earlier studies of cAMP and the steroid hormones.
The binding proteins described in this paper have the affinity and specificity for cGMP which would be expected of a physiological receptor. In fact, with slightly different binding conditions than those described, the peak 2 protein is being used for the assay of cGMP (manuscript in preparation). The tissue distribution of cGMP binding generally parallels the cGMP levels in these tissues. In some tissues (lung, cerebellum, intestine) the total cGMP binding activity approaches that for cAMP when assayed at pH 7. Low levels of cAMP-binding activity are also found in some of these tissues. In order that our results could reflect more closely the physiological situation, we have avoided conducting binding assays at pH 4.0, where cGMP is known to bind to some forms of cAMP-dependent protein kinases with high affinity (14) .
The finding that the cGMP dependence of protein kinase activity of peak 2 was observed only at low histone concentrations was unexpected, particularly in view of the fact that cAMP affects the Vma, for protein substrates of the cAMP-dependent protein kinase (21) . This suggests a basic difference in the mechanism of activation of cGMP-dependent protein kinase compared with the cAMP-dependent protein kinase. Furthermore, preliminary studies using Sephadex G-100 chromatography (22) indicate that cGMP does not readily dissociate the cGMP-dependent protein kinase into lower molecular weight regulatory and catalytic subunits as is the case for cAMP dissociation of cAMP-dependent protein kinase (unpublished observations). These data indicate that the manner in which cGMP activates the cGMP-dependent protein kinase cannot always be considered analogous to the mechanism by which cAMP activates the cAMP-dependent protein kinase. The lack of cGMP-dependent protein kinase activity associated with peak 1 could reflect the relative impurity of this binding protein. As mentioned above, the possibility must be considered that this peak represents a breakdown product of peak 2, and that this modification could result in the loss of cGMP sensitivity.
